Resumo

MENDIVIL A, Carlos Olimpo. Orlistat and Sibutramine in the management of metabolic syndrome. Acta Med Colomb [online]. 2005, vol.30, n.3, pp.168-170. ISSN 0120-2448.

Increased body fat mass is associated with a reduction in insulin sensitivity and the development of a myriad disorders characteristic of the metabolic syndrome. On the other hand, a reduction in the amount of body fat improves those alterations significantly. There are currently two medications approved for the management of excess weight and obesity: Orlistat and sibutramine. The purpose of this paper is to review the main pharmacological and clinical properties of both molecules, emphazising their impact on the components of metabolic syndrome.

Palavras-chave : obesity; metabolic syndrome; orlistat; sibutramine.